[18F]氟代噻蒽曲司PET在卵巢癌中的应用:与[18F]FDG PET、病灶位置、肿瘤分级及乳腺癌基因突变状态的比较
研究纳入14例上皮性卵巢癌患者,在新肿瘤治疗前同时行[18F]FTT(PARP1显像)和[18F]FDG PET,比较55个病灶的SUVmax。结果未发现[18F]FTT与[18F]FDG的SUVmax相关,[18F]FTT摄取在不同病灶间差异大,且与肿瘤位置、分级或BRCA1/2状态无显著差异。
要点
- 14例上皮性卵巢癌患者共55个病灶,均于新治疗前行[18F]FTT与[18F]FDG PET。
- 每病灶[18F]FTT与[18F]FDG的SUVmax无相关性,提示二者靶点不同。
- [18F]FTT SUVmax与肿瘤位置、分级或BRCA1/2状态均无显著差异。
核心结论
- 研究提示[18F]FTT PET可能提供不同于[18F]FDG PET及常用肿瘤特征的卵巢癌信息。
- 结果提示所研究的卵巢肿瘤中PARP1表达范围广泛,且不能由[18F]FDG PET、位置、分级或突变状态解释。
研究设计与样本
- 上皮性卵巢癌受试者在新肿瘤治疗前接受[18F]FTT和[18F]FDG PET。
- 14例受试者共识别55个病灶。
- 比较每病灶[18F]FTT与[18F]FDG的SUVmax,并将[18F]FTT SUVmax与肿瘤位置、分级及胚系或体细胞BRCA1/2状态比较。
- 采用线性混合模型识别受试者水平差异。
主要发现
- 每病灶[18F]FTT SUVmax与[18F]FDG SUVmax之间无相关性。
- [18F]FTT摄取在不同病灶间差异广泛。
- [18F]FTT平均SUVmax与肿瘤位置、分级或BRCA1/2状态之间无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Poly(adenosine diphosphate-ribose) polymerase-1 (PARP1) inhibitors have improved ovarian cancer treatment outcomes. However, clinical response remains heterogeneous. Existing biomarkers, mainly breast cancer susceptibility genes 1 and 2 (BRCA1/2), are suboptimal. New tools are needed to guide patient selection. In this study, [18F]fluorthanatrace ([18F]FTT), a PET radiotracer for imaging PARP1, was compared with [18F]FDG and tumor features commonly assessed in ovarian cancer. Methods: Subjects with epithelial ovarian cancer underwent both [18F]FTT and [18F]FDG PET before new oncologic treatment. The SUVmax of [18F]FTT and [18F]FDG was compared between lesions. [18F]FTT SUVmax was compared with tumor location, tumor grade, and germline or somatic BRCA1/2 status. Linear mixed models were fitted to identify subject-level differences. Results: Fifty-five lesions were identified in 14 subjects. No correlation was found between [18F]FTT SUVmax and [18F]FDG SUVmax per lesion, supporting distinct molecular targets. [18F]FTT uptake varied widely across lesions, with no significant differences between mean SUVmax and tumor location, grade, or BRCA1/2 status. Conclusion: Our findings suggest that [18F]FTT PET may provide unique information on ovarian cancer distinct from [18F]FDG PET and commonly assessed tumor features. Our results imply a wide range of PARP1 expression in the studied ovarian tumors not explained by [18F]FDG PET, location, grade, or mutational status.
引用
- Weeks JK, Pantel AR, Gitto SB, et al. [18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status. J Nucl Med. 2025. PMID: 39638432. doi:10.2967/jnumed.124.267627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。